Research programme: anorectants - Abbott/Tularik

Drug Profile

Research programme: anorectants - Abbott/Tularik

Alternative Names: Anorectants research programme - Abbott/Tularik; Antiobesity agents research programme - Abbott/Tularik; Research programme: antiobesity agents - Abbott/Tularik

Latest Information Update: 11 Dec 2001

Price : $50

At a glance

  • Originator Abbott GmbH & Co. KG; Tularik
  • Developer Tularik
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Obesity

Most Recent Events

  • 11 Dec 2001 Discontinued-Preclinical for Obesity in USA (Unknown route)
  • 18 Jun 2001 Knoll notified Tularik that it is terminating the collaboration in obesity from October 31, 2001
  • 13 Mar 2001 BASF's pharmaceutical business has been acquired by Abbott Laboratories
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top